BAKU, Azerbaijan, Dec. 15
By Nargiz Sadikhova - Trend:
Twelve new animal vaccines developed and manufactured by Kazakhstan-based Antigen enterprise will be exported to Europe thanks to the EBRD advisory client in Kazakhstan, Trend reports citing European Bank for Reconstruction and Development (EBRD).
The EBRD said that thanks to a project funded by the Kazakhstan government, the vaccines will be sold abroad. With the help of international advisers, the company was able to conform to the requirements of globally recognized Good Manufacturing Practices (GMP), ensuring vaccine accreditation.
The enterprise now strives to produce modern, easy-to-administer vaccines that provide additional benefits. Antigen has already increased export sales to Azerbaijan, Georgia, Mongolia and the Kyrgyz Republic. It will soon start exports to Europe.
Antigen continues to work with international advisers beyond the EBRD project to further develop the business.
The enterprise has expanded its production of growth media beyond veterinary applications with transportable growth media for the healthcare industry.
It also offers one of the best testing laboratories for dairy, honey and other bee products in Kazakhstan. Antigen, which was established in 1998 as a small research and development laboratory, is now a prominent driver of new technologies in the country and holds 150 patent rights.
To date, the EBRD has invested almost €8.6 billion through 276 projects in the economy of the Republic of Kazakhstan.
---
Follow the author on twitter: @nargiz_sadikh